Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014
Dateline City:
WHITEHOUSE STATION, N.J.
KEYTRUDA® monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer
Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data on the investigational
use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1
therapy – in PD-L1 positive, advanced gastric cancer. The early findings
presented showed an overall response rate (confirmed and unconfirmed) of
31 percent with KEYTRUDA as monotherapy, as measured by investigator
assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47).
Language:
English
Contact:
MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Merck | Pharmaceuticals | Study